Cargando…
Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China
China’s hepatitis B virus (HBV) prevention policy has been evaluated through nationally representative serologic surveys conducted in 1992 and 2006. We report results of a 2014 serologic survey and reanalysis of the 1992 and 2006 surveys in the context of program policy. The 2014 survey used a 2-sta...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403029/ https://www.ncbi.nlm.nih.gov/pubmed/28418296 http://dx.doi.org/10.3201/eid2305.161477 |
_version_ | 1783231352627265536 |
---|---|
author | Cui, Fuqiang Shen, Lipin Li, Li Wang, Huaqing Wang, Fuzhen Bi, Shengli Liu, Jianhua Zhang, Guomin Wang, Feng Zheng, Hui Sun, Xiaojin Miao, Ning Yin, Zundong Feng, Zijian Liang, Xiaofeng Wang, Yu |
author_facet | Cui, Fuqiang Shen, Lipin Li, Li Wang, Huaqing Wang, Fuzhen Bi, Shengli Liu, Jianhua Zhang, Guomin Wang, Feng Zheng, Hui Sun, Xiaojin Miao, Ning Yin, Zundong Feng, Zijian Liang, Xiaofeng Wang, Yu |
author_sort | Cui, Fuqiang |
collection | PubMed |
description | China’s hepatitis B virus (HBV) prevention policy has been evaluated through nationally representative serologic surveys conducted in 1992 and 2006. We report results of a 2014 serologic survey and reanalysis of the 1992 and 2006 surveys in the context of program policy. The 2014 survey used a 2-stage sample strategy in which townships were selected from 160 longstanding, nationally representative, county-level disease surveillance points, and persons 1–29 years of age were invited to participate. The 2014 sample size was 31,713; the response rate was 83.3%. Compared with the 1992 pre–recombinant vaccine survey, HBV surface antigen prevalence declined 46% by 2006 and by 52% by 2014. Among children <5 years of age, the decline was 97%. China’s HBV prevention program, targeted toward interrupting perinatal transmission, has been highly successful and increasingly effective. However, this progress must be sustained for decades to come, and elimination of HBV transmission will require augmented strategies. |
format | Online Article Text |
id | pubmed-5403029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-54030292017-05-12 Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China Cui, Fuqiang Shen, Lipin Li, Li Wang, Huaqing Wang, Fuzhen Bi, Shengli Liu, Jianhua Zhang, Guomin Wang, Feng Zheng, Hui Sun, Xiaojin Miao, Ning Yin, Zundong Feng, Zijian Liang, Xiaofeng Wang, Yu Emerg Infect Dis Research China’s hepatitis B virus (HBV) prevention policy has been evaluated through nationally representative serologic surveys conducted in 1992 and 2006. We report results of a 2014 serologic survey and reanalysis of the 1992 and 2006 surveys in the context of program policy. The 2014 survey used a 2-stage sample strategy in which townships were selected from 160 longstanding, nationally representative, county-level disease surveillance points, and persons 1–29 years of age were invited to participate. The 2014 sample size was 31,713; the response rate was 83.3%. Compared with the 1992 pre–recombinant vaccine survey, HBV surface antigen prevalence declined 46% by 2006 and by 52% by 2014. Among children <5 years of age, the decline was 97%. China’s HBV prevention program, targeted toward interrupting perinatal transmission, has been highly successful and increasingly effective. However, this progress must be sustained for decades to come, and elimination of HBV transmission will require augmented strategies. Centers for Disease Control and Prevention 2017-05 /pmc/articles/PMC5403029/ /pubmed/28418296 http://dx.doi.org/10.3201/eid2305.161477 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Cui, Fuqiang Shen, Lipin Li, Li Wang, Huaqing Wang, Fuzhen Bi, Shengli Liu, Jianhua Zhang, Guomin Wang, Feng Zheng, Hui Sun, Xiaojin Miao, Ning Yin, Zundong Feng, Zijian Liang, Xiaofeng Wang, Yu Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China |
title | Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China |
title_full | Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China |
title_fullStr | Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China |
title_full_unstemmed | Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China |
title_short | Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China |
title_sort | prevention of chronic hepatitis b after 3 decades of escalating vaccination policy, china |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403029/ https://www.ncbi.nlm.nih.gov/pubmed/28418296 http://dx.doi.org/10.3201/eid2305.161477 |
work_keys_str_mv | AT cuifuqiang preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT shenlipin preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT lili preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT wanghuaqing preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT wangfuzhen preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT bishengli preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT liujianhua preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT zhangguomin preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT wangfeng preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT zhenghui preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT sunxiaojin preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT miaoning preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT yinzundong preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT fengzijian preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT liangxiaofeng preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina AT wangyu preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina |